Unknown

Dataset Information

0

A Bayesian Phase I/II Trial Design for Immunotherapy.


ABSTRACT: Immunotherapy is an innovative treatment approach that stimulates a patient's immune system to fight cancer. It demonstrates characteristics distinct from conventional chemotherapy and stands to revolutionize cancer treatment. We propose a Bayesian phase I/II dosefinding design that incorporates the unique features of immunotherapy by simultaneously considering three outcomes: immune response, toxicity and efficacy. The objective is to identify the biologically optimal dose, defined as the dose with the highest desirability in the risk-benefit tradeoff. An Emax model is utilized to describe the marginal distribution of the immune response. Conditional on the immune response, we jointly model toxicity and efficacy using a latent variable approach. Using the accumulating data, we adaptively randomize patients to experimental doses based on the continuously updated model estimates. A simulation study shows that our proposed design has good operating characteristics in terms of selecting the target dose and allocating patients to the target dose.

SUBMITTER: Liu S 

PROVIDER: S-EPMC6860919 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Bayesian Phase I/II Trial Design for Immunotherapy.

Liu Suyu S   Guo Beibei B   Yuan Ying Y  

Journal of the American Statistical Association 20180628 523


Immunotherapy is an innovative treatment approach that stimulates a patient's immune system to fight cancer. It demonstrates characteristics distinct from conventional chemotherapy and stands to revolutionize cancer treatment. We propose a Bayesian phase I/II dosefinding design that incorporates the unique features of immunotherapy by simultaneously considering three outcomes: immune response, toxicity and efficacy. The objective is to identify the biologically optimal dose, defined as the dose  ...[more]

Similar Datasets

| S-EPMC8204709 | biostudies-literature
| S-EPMC5687612 | biostudies-literature
| S-EPMC3075947 | biostudies-literature
| S-EPMC9438402 | biostudies-literature
| S-EPMC7483235 | biostudies-literature
| S-EPMC10504821 | biostudies-literature
| S-EPMC9199061 | biostudies-literature
| S-EPMC4667689 | biostudies-literature
| S-EPMC8606333 | biostudies-literature
| S-EPMC10102885 | biostudies-literature